Diltiazem Tablets/Capsules Suppliers & Bulk Manufacturers
Available Forms: Tablet/Capsules
Available Strengths: IR: 0 mg, 60 mg, 90 mg, 120 mg; SR: Up to 540 mg
Reference Brands: Cardizem(US); Dilzem(EU)
Category:
Heart Disorder
Diltiazem is a calcium channel blocker that relaxes blood vessels and reduces heart rate by inhibiting calcium entry into cardiac and vascular smooth muscle cells. It effectively treats hypertension, angina, and arrhythmias, providing benefits like lowered blood pressure, decreased chest pain, rhythm stabilization, and improved overall cardiovascular health.
Diltiazem tablets/capsules is available in Tablet/Capsules
and strengths such as IR: 0 mg, 60 mg, 90 mg, 120 mg; SR: Up to 540 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Diltiazem tablets/capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Diltiazem tablets/capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Diltiazem tablets and capsules, marketed as Cardizem and Dilzem, are approved in the US by the FDA and in the EU via EMA for hypertension, angina, and arrhythmias. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, FDA reviews clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional compliance supports timely approval, safe use, and global availability, enabling effective cardiovascular management worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing